8-K current report · filed Oct 29, 2026

Coherus Oncology, Inc. (CHRS) 8-K Current Report: October 29, 2026

Item 8.01Item EX-99.1Item 7.01CHRS overview

Short answer

Coherus Oncology, Inc. (CHRS) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Interim clinical data announced from TREGCHECK™ program evaluating tagmokitug in combination with toripalimab.

Coherus Oncology, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Interim clinical data announced from TREGCHECK™ program evaluating tagmokitug in combination with toripalimab
  • Study includes regimens with or without chemotherapy
  • Tagmokitug is an investigational cytolytic CCR8 antibody, making data relevant to oncology pipeline valuation
  • Exhibit 99.1 contains the detailed efficacy and safety results, if available

Item 8.01 · Other Events

  • Tagmokitug showed strongest signal in first-line ESCC: post-cutoff cORR 89% (8/9), including 100% in PD-L1-positive patients
  • Second-line ESCC 700 mg arm: 16.7% cORR, 33.3% CBR and 5.5-month mPFS versus ~3.4-month chemotherapy benchmark
  • Activity extended to upper-GI cancers: 700 mg produced 23.5% cORR in GC/GEJ/EAC, with responses in EAC and PD-1-resistant disease
  • Safety appears manageable, but Grade 3-5 immune-related adverse events occurred in 20% of 120 combination-treated patients
  • Enrollment expansion planned in first- and second-line ESCC, making follow-up durability, PFS and biomarker data key catalysts

Item EX-99.1 · Exhibit EX-99.1

  • Tagmokitug first-line ESCC data strengthened development case: cORR 75% across PD-L1 status and 100% in PD-L1-positive patients
  • Post-cutoff cORR increased to 89% (8/9), but based on a very small, early-stage efficacy dataset
  • Second-line 700 mg cohort showed 16.7% cORR, 33.3% clinical benefit rate and 5.5-month median PFS
  • Activity extended across HNSCC and upper-GI tumors, including 23.5% cORR at 700 mg in evaluable upper-GI patients
  • Safety remained manageable across more than 120 combination-treated patients, with 20% Grade 3-5 immune-related adverse events

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Coherus Oncology, Inc. 8-K filings

Get the next CHRS 8-K as it lands

Follow CHRS for push alerts, or ask the research agent what this filing means.